1. Introduction {#sec1-marinedrugs-17-00649}
===============

Fungal secondary metabolites have always been considered an important source for drug discovery due to their diverse chemical structures and bioactivities \[[@B1-marinedrugs-17-00649]\]. Among them, *Penicillium* are recognized as important producers of structurally unusual natural products, especially of terpenes with pharmaceutical potential as illustrated with chrysogenester, an anti-inflammatory meroterpenoid-type derivative \[[@B2-marinedrugs-17-00649]\], shearilicine, a cytotoxic indole-diterpenoid possessing a rare carbazole unit \[[@B3-marinedrugs-17-00649],[@B4-marinedrugs-17-00649]\], and the penerpenes, unusual indole-terpenoids which have shown potent protein tyrosine phosphatase inhibitory activity \[[@B5-marinedrugs-17-00649]\]. Insecticidal agents were also reported for penicianstinoid A, an austinoid-like meroterpenoid \[[@B6-marinedrugs-17-00649]\], as well as plant regulators for the dongtingnoids, diterpenoid glycosides which revealed promising seed-germination-promoting activities \[[@B7-marinedrugs-17-00649]\]. Accordingly, strains of *Penicillium* have gained considerable attention due to their ability to produce unusual secondary metabolites and have proved to be a prolific source of bioactive compounds.

In our search for new bioactive compounds from fungal sources \[[@B6-marinedrugs-17-00649],[@B8-marinedrugs-17-00649],[@B9-marinedrugs-17-00649]\], the fungus *Penicillium* sp. JY246 was isolated from the mangrove's stem *Ceriops tagal*, collected from the South China Sea. The EtOAc extract of the fermentation broth showed significant activity against newly hatched larvae of *Helicoverpa armigera* Hubner. Chemical investigation of the fungus fermentation's organic extract resulted in the isolation of four new xanthene derivatives (**1**--**4**), along with one known compound **5** ([Figure 1](#marinedrugs-17-00649-f001){ref-type="fig"}). Herein, the isolation, structure elucidation, and insecticidal activity of these compounds are described.

2. Results and Discussion {#sec2-marinedrugs-17-00649}
=========================

2.1. Structure Elucidation {#sec2dot1-marinedrugs-17-00649}
--------------------------

Compound **1** was obtained as a white amorphous powder, and its molecular formula was determined to be C~16~H~14~O~3~ based on HRESIMS ([Figure S8](#app1-marinedrugs-17-00649){ref-type="app"}), accounting for 10 degrees of unsaturation. Analysis of the ^1^H NMR spectrum ([Table 1](#marinedrugs-17-00649-t001){ref-type="table"}, [Figure S1](#app1-marinedrugs-17-00649){ref-type="app"}) displayed six olefinic proton signals at *δ*~H~ 7.05 (dd, *J* = 8.4, 8.4 Hz, H-6), 7.04 (dd, *J* = 8.0, 8.0 Hz, H-3), 6.58 (dd, *J* = 8.0, 0.8 Hz, H-4), 6.55 (dd, *J* = 8.0, 0.8 Hz, H-2), 6.52 (dd, *J* = 8.4, 1.2 Hz, H-5), and 6.50 (dd, *J* = 8.4, 1.2 Hz, H-7); two methine signals at *δ*~H~ 4.64 (m, H-11) and 3.99 (dd, *J* = 12.4, 4.0 Hz, H-9); one methylene group at *δ*~H~ 3.17 (ddd, *J* = 13.2, 4.0, 1.6 Hz, H-10b) and 1.79 (dt, *J* = 12.4, 6.4 Hz, H-10a); and one methyl signal at *δ*~H~ 1.39 (d, *J* = 6.4 Hz, H-12). Interpretation of the ^13^C NMR and DEPT spectra ([Table 2](#marinedrugs-17-00649-t002){ref-type="table"}, [Figures S2 and S3](#app1-marinedrugs-17-00649){ref-type="app"}) revealed 16 carbon signals, attributable to twelve sp^2^-hybridized carbons (*δ*~C~ 156.9, 154.3, 152.3, 150.1, 127.9, 127.8, 110.4, 110.2, 109.3, 109.1, 107.0 and 106.5) indicating the presence of two benzene rings, two sp^3^ methine groups (*δ*~C~ 71.7 and 22.3), one sp^3^ methylene group (*δ*~C~ 33.0), and one methyl group (*δ*~C~ 20.7). The detailed structure of **1** was identified by interpretation of the COSY ([Figure S6](#app1-marinedrugs-17-00649){ref-type="app"}) and HMBC spectra ([Figure 2](#marinedrugs-17-00649-f002){ref-type="fig"} and [Figure S5](#app1-marinedrugs-17-00649){ref-type="app"}). The key HMBC correlations from H-9 to C-4a/C-4b, and further---H-10b to C-8a/C-8b, H-11 to C-8/C-9, and H~3~-12 to C-10/C-11---indicate that C-9 linked the two benzene rings at C-8a/C-8b, and the HMBC correlations from H-3 to C-4a and H-6 to C-4b indicated the presence of one oxygen bridge between C-4a and C-4b. So, the two benzene rings were connected through C-9 and oxygen-bridge to build up the skeleton of 9-methylene-9*H*-xanthene \[[@B10-marinedrugs-17-00649]\]. Furthermore, C-11 linked to C-8 through the oxygen bridge was deduced by chemical shift at C-8 (*δ*~C~ 154.3) and C-11 (*δ*~C~ 71.7). Hereto, the planar structure of **1** was elucidated ([Figure 1](#marinedrugs-17-00649-f001){ref-type="fig"}).

The relative configuration of **1** was revealed by the NOESY experiment ([Figure 3](#marinedrugs-17-00649-f003){ref-type="fig"} and [Figure S7](#app1-marinedrugs-17-00649){ref-type="app"}). The NOESY correlations of H-9 to H~3~-12 indicated that H-9 and H~3~-12 were on the contrary side of the H-11. The absolute configuration of **1** was determined by comparing experimental and calculated electronic circular dichroism (ECD) spectra for the truncated model (9*R*, 11*S*)-**1** and the truncated model (9*S*, 11*R*)-**1** using time-dependent density-functional theory (TDDFT). The DFT reoptimization of the initial Merck molecular force field (MMFF) minima was performed at the B3LYP/6 − 31 + *g* (d, p) level with a conductor-like polarizable continuum model (CPCM) solvent model for MeOH \[[@B11-marinedrugs-17-00649]\]. The theoretical spectrum of **1** showed the same Cotton effect with the experimental plot recorded in MeOH ([Figure 4](#marinedrugs-17-00649-f004){ref-type="fig"}), which supported that the absolute configuration was 9*S*, 11*R*. Thus, the completed structure of **1** was elucidated as depicted in [Figure 1](#marinedrugs-17-00649-f001){ref-type="fig"}, and was named penicixanthene A.

Compound **2** was isolated as a colorless amorphous powder. The molecular formula of **2** was determined to be C~20~H~22~O~5~ (10 degrees of unsaturation) by HRESIMS ([Figure S16](#app1-marinedrugs-17-00649){ref-type="app"}). The ^1^H and ^13^C NMR data ([Table 1](#marinedrugs-17-00649-t001){ref-type="table"} and [Table 2](#marinedrugs-17-00649-t002){ref-type="table"}, [Figures S9 and S10](#app1-marinedrugs-17-00649){ref-type="app"}) revealed that **2** belongs to the 9-methylene-9*H*-xanthene class \[[@B10-marinedrugs-17-00649]\], and suggested a close structural relationship to **1**. The obvious differences in ^1^H NMR spectrum were the disappearance of two aromatic protons signals at *δ*~H~ 6.50/H-5 and *δ*~H~ 7.05/H-6 in **2**. In addition, in the ^13^C NMR spectra, the C-5/C-6 signals moved downfield *δ*~C~ 110.2/127.9 in **1** vs*. δ*~C~ 110.7/157.3 in **2**, indicating that the disappearance of two aromatic protons were respectively replaced by a butan-1-one unit at C-5 and a hydroxy group at C-6 in **2**, which was further supported by HMBC ([Figure S13](#app1-marinedrugs-17-00649){ref-type="app"}). The existence of the butan-1-one unit was confirmed by HMBC correlations from H-14 to C-5/C-13/C-16, H-15 to C-13/C-14, and H-16 to C-14/C-15.

Furthermore, the oxygen-bridge between C-11 to C-8 in **1** was broken in **2**. The C-8 signal moved high-field significantly at *δ*~C~ 134.4 in **2** vs. *δ*~C~ 154.3 in **1** in the ^13^C NMR spectrum, and the H-8 signal at *δ*~H~ 6.69 in **2** in the ^1^H NMR spectrum, indicating that oxygen function at C-8 in **1** was replaced by an aromatic proton in **2**, which was confirmed by HMBC correlations ([Figure 2](#marinedrugs-17-00649-f002){ref-type="fig"}) of H-7 to C-5/C-8a, H-8 to C-4b/C-6/C-9, H-9 to C-4a/C-4b, H-10 to C-8a/C-8b, H-11 to C-9, and H~3~-12 to C-10/C-11. The ^1^H-^1^H COSY ([Figure S14](#app1-marinedrugs-17-00649){ref-type="app"}) and HMBC spectra allowed the complete assignment of **2**. The absolute configuration of C-9 in **2** was resolved by comparing experimental and calculated ECD spectra using TDDFT ([Figure 4](#marinedrugs-17-00649-f004){ref-type="fig"}) \[[@B11-marinedrugs-17-00649]\]. The absolute configuration of C-11 was determined by making MTPA esters of **2** \[[@B12-marinedrugs-17-00649]\], and the differences in ^1^H NMR ([Figures S33 and S35](#app1-marinedrugs-17-00649){ref-type="app"}) chemical shifts between (*S*)- and (*R*)-MTPA esters (Δ*δ* = *δ~S~* − *δ~R~*) ([Figure 5](#marinedrugs-17-00649-f005){ref-type="fig"}) were calculated to assign the absolute configuration of C-11 to be *R*. Thus, the absolute configuration of **2** was established as 9*R*, 11*R*, and it was named penicixanthene B.

Compound **3**, isolated as a colorless amorphous powder, was evidenced to have a molecular formula of C~20~H~22~O~5~ (10 degrees of unsaturation) from its HRESIMS data ([Figure S24](#app1-marinedrugs-17-00649){ref-type="app"}). The similarities in the NMR data ([Figures S17 and S18](#app1-marinedrugs-17-00649){ref-type="app"}) for **3** and **2** suggested that **3** was structurally similar to **2**, with the main differences being the chemical shifts of C-8b/C-9/C-10 ([Table 2](#marinedrugs-17-00649-t002){ref-type="table"}) and the coupling constants of H-9/H-10 ([Table 1](#marinedrugs-17-00649-t001){ref-type="table"}), and as indicated by the small coupling constant *J*~9,10~ = 1.2 Hz and 2D NMR data in **3** (vs. the coupling constant *J*~9,10~ = 8.0 Hz in **2**) \[[@B13-marinedrugs-17-00649]\], implying that the H-9 orientation of **3** was different from that of **2**. The absolute configuration of C-9 in **3** was established by comparison of experimental and calculated electronic circular dichroism (ECD) data \[[@B11-marinedrugs-17-00649]\]. The experimental spectrum of **3** showed the opposite Cotton effect with the experimental results of **2** recorded in MeOH ([Figure 4](#marinedrugs-17-00649-f004){ref-type="fig"}), which supported that the absolute configuration of C-9 in **3** was 9*S*. The absolute configuration of C-11 was determined by making MTPA esters of **3** \[[@B12-marinedrugs-17-00649]\]. The differences in ^1^H NMR ([Figures S37 and S39](#app1-marinedrugs-17-00649){ref-type="app"}) chemical shifts between (*S*)- and (*R*)-MTPA esters (Δ*δ* = *δ~S~* − *δ~R~*) ([Figure 5](#marinedrugs-17-00649-f005){ref-type="fig"}) were calculated to assign the absolute configuration of C-11 to be *R*. Thus, the absolute configuration of **3** was assigned as 9*S*, 11*R*, and the structure of **3** was defined as penicixanthene C.

Compound **4** was obtained as white amorphous powder, and the molecular formula was deduced to be C~21~H~24~O~5~ on the basis of HRESIMS ([Figure S32](#app1-marinedrugs-17-00649){ref-type="app"}), implying 10 degrees of unsaturation. Analysis of the ^1^H NMR spectrum ([Table 1](#marinedrugs-17-00649-t001){ref-type="table"}, [Figure S25](#app1-marinedrugs-17-00649){ref-type="app"}) displayed signals corresponding to five olefinic protons signal at *δ*~H~ 7.24 (dd, *J* = 8.0, 8.0 Hz, H-3), 7.06 (d, *J* = 8.0 Hz, H-4), 6.81 (d, *J* = 8.0 Hz, H-2), 6.22 (d, *J* = 8.4 Hz, H-8), and 6.05 (d, *J* = 8.4 Hz, H-7); two methine signals at *δ*~H~ 4.72 (m, H-12) and 4.63 (m, H-9); four methylene groups at *δ*~H~ 3.12 (t, *J* = 7.2 Hz, H-14), 2.22 (m, H-10b), 1.81 (m H-10a), 1.74 (m, H-11), and 1.72 (m, H-15); and two methyl groups at *δ*~H~ 3.57 (s, H-17) and 0.99 (t, *J* = 7.2 Hz, H-16). The ^13^C NMR spectrum ([Table 2](#marinedrugs-17-00649-t002){ref-type="table"}, [Figure S26](#app1-marinedrugs-17-00649){ref-type="app"}) displayed 21 signals, which were classified by DEPT ([Figure S27](#app1-marinedrugs-17-00649){ref-type="app"}) and HMQC spectra ([Figure S28](#app1-marinedrugs-17-00649){ref-type="app"}) as twelve sp^2^-hybridized carbons (*δ*~C~ 162.1, 159.7, 158.3, 141.6, 135.6, 128.9, 128.3, 125.4, 123.3, 110.9, 110.8, and 105.8) indicating the presence of two benzene rings, two sp^3^ methine groups (*δ*~C~ 67.9 and 32.3), four sp^3^ methylene groups (*δ*~C~ 47.2, 28.2, 23.9, and 19.2), and two methyl groups (*δ*~C~ 59.9 and 14.3). The above NMR spectroscopic data indicated the presence of a structure similar to nodulisporin F \[[@B13-marinedrugs-17-00649]\] with two subunits. One of the subunits was similar to **5** \[[@B14-marinedrugs-17-00649]\], isolated from the same source. The other subunit showed signals corresponding to the naphthalene part. The locations of connection between the two units at C-8a/C-9 were evidenced from HMBC correlations ([Figure 2](#marinedrugs-17-00649-f002){ref-type="fig"}, [Figure S29](#app1-marinedrugs-17-00649){ref-type="app"}) of H-9 to C-4a/C-4b/C-8/C-8a/C-8b, as well as from H-8 to C-9. Based on the above data, the naphthalene part of **4** was linked to a 1-(2,6-dihydroxyphenyl)-butan-1-one moiety in para-position to the phenol group (at C-9). In addition, the C-4a and C-12 in **4** were replaced by a methoxyl group and a hydroxy group, respectively.

The relative configuration of **4** was based on the NOESY ([Figure S31](#app1-marinedrugs-17-00649){ref-type="app"}) correlations, as indicated in [Figure 3](#marinedrugs-17-00649-f003){ref-type="fig"}. The NOESY correlations of H-9 to H-10a, H-11a, and H-12, as well as H-10b to H-11b, indicated that H-9, H-10a, H-11a, and H-12 were on the contrary side of the H-10b and H-11b. The absolute configuration of **4** was elucidated as 9*R*, 12*R* by comparing its experimental ECD spectrum to the calculated spectrum ([Figure 4](#marinedrugs-17-00649-f004){ref-type="fig"}) \[[@B11-marinedrugs-17-00649]\]. The structure of **4** was assigned, named as penicixanthene D.

2.2. Biological Activity {#sec2dot2-marinedrugs-17-00649}
------------------------

Compounds **1**--**5** were examined for insecticidal activity. In the test, we set up three parallel trials. Compounds **2** and **3** showed growth inhibition activities against newly hatched larvae of *Helicoverpa armigera* Hubner with the IC~50~ values 100 and 200 μg/mL, respectively. Azadirachtin was used as positive control with the IC~50~ value of 25 μg/mL. Compounds **1**, **3**, and **4** showed insecticidal activity against newly hatched larvae of *Culex quinquefasciatus* with LC~50~ values of 38.5 (±1.16), 11.6 (±0.58) and 20.5 (±1) μg/mL, respectively. Azadirachtin was used as positive control with the LC~50~ value of 8.8 (±0.58) μg/mL ([Table 3](#marinedrugs-17-00649-t003){ref-type="table"}).

3. Materials and Methods {#sec3-marinedrugs-17-00649}
========================

3.1. General Experimental Procedures {#sec3dot1-marinedrugs-17-00649}
------------------------------------

Optical rotations were measured on a JASCO P-1020 digital polarimeter (JASCO, Tokyo, Japan). IR spectra were recorded on a Thermo Nicolet 6700 (using KBr disks) spectrophotometer (Thermo, Madison, USA). 1D and 2D NMR spectra were measured on a Bruker AV-400 spectrometer with TMS as the internal standard (Bruker Corporation, Fällanden, Switzerland) (The PULPROG for testing NOESY was noesygpphpp, the temperature was 300 K, and the mix time of NOESY was 0.3 s). HRESIMS spectra were obtained on a Q-TOF Ultima Global GAA076 LC mass spectrometer (Waters, Milford, MA, USA). Preparative HPLC was used for an Agilent 1260 prep-HPLC system with an Agilent Eclipse XDB-C18 column (250 mm × 9.4 mm, 7 µm, Agilent Corporation, Santa Clara, CA, USA). The other experimental procedures were performed as reported previously \[[@B6-marinedrugs-17-00649]\].

3.2. Fungal Materials {#sec3dot2-marinedrugs-17-00649}
---------------------

The fungal strain *Penicillium* sp. JY246 was isolated from the stem of mangrove *Ceriops tagal*, collected in the South China Sea in July 2016. The fungus was identified according to its morphological characteristics and by comparison of the internal transcribed spacer (ITS) sequence amplification, primer pair ITS1 and ITS4 and sequencing of the ITS region. The sequence data has been submitted to GenBank with the accession number MK050979, and identified as *Penicillium*.

The fungal strain was cultivated in 20 L potato glucose liquid medium (15 g of glucose and 30 g of sea salt in 1 L of potato infusion, in 1 L Erlenmeyer flasks each containing 300 mL of culture broth) at 25 °C without shaking for 4 weeks.

3.3. Extraction and Isolation {#sec3dot3-marinedrugs-17-00649}
-----------------------------

The fungal cultures were filtered through cheesecloth, and the filtrate was extracted with EtOAc (3 *×* 20 L, 24 h each). The organic extracts were concentrated in vacuo to yield an oily residue (23.6 g), which was subjected to silica gel column chromatography (CC) (petroleum ether, EtOAc *v/v*, gradient 100:0--0:100) to generate five fractions (Fr. 1--Fr. 5). Fraction Fr. 4 (5 g) was separated by silica gel CC and eluted with petroleum ether-EtOAc (from 3:1 to 0:1) to afford four subfractions (**4a**--**4d**). Subfraction **4b** were further separated by semi-preparative HPLC (MeOH--H~2~O, 45:55, *v*/*v*) to obtain **1** (6.0 mg), **4** (4.5 mg), and **5** (5.0 mg), and subfraction **4c** was further separated by semi-preparative HPLC with MeOH--H~2~O (35:65 *v*/*v*) to give **2** (3.3 mg) and **3** (3.5 mg).

*Penicixanthene* A (**1**)*:* white amorphous powder. \[*α*\]${}_{D}^{24}$ − 10.7 (*c* = 0.02, CHCl~3~). CD (*c* 2 × 10^-4^ mol/L, MeOH) *λ*~max~ (Δ*ε*) 211 (+11.8), 242 (−0.1), 269 (+1.1) nm; IR (KBr) *ν*~max~ 3405, 2923, 1747, 1740, 1230, 1064, 756 cm^-1^; ^1^H and ^13^C NMR see [Table 1](#marinedrugs-17-00649-t001){ref-type="table"} and [Table 2](#marinedrugs-17-00649-t002){ref-type="table"}; HRESIMS *m/z* 255.1012 \[M + H\]^+^ (calcd. For C~16~H~15~O~3~, 255.1016).

*Penicixanthene* B (**2**)*:* white amorphous powder. \[*α*\]${}_{D}^{24}$ -- 9.5 (*c* = 0.02, CHCl~3~). CD (*c* 2 × 10^-4^ mol/L, MeOH) *λ*~max~ (Δ*ε*) 207 (−19.6), 232 (+4.2), 252 (+0.8), 286 (+0.8) nm; IR (KBr) *ν*~max~ 3402, 2944, 1747, 1410, 1250, 1064, 818 cm^-1^; ^1^H and ^13^C NMR see [Table 1](#marinedrugs-17-00649-t001){ref-type="table"} and [Table 2](#marinedrugs-17-00649-t002){ref-type="table"}; HRESIMS *m/z* 343.1537 \[M + H\]^+^ (calcd. for C~20~H~23~O~5~, 343.1540).

*Penicixanthene* C (**3**): white amorphous powder. \[*α*\]${}_{D}^{24}$ + 10.7 (*c* = 0.10, CHCl~3~). CD (*c* 2 × 10^-4^ mol/L, MeOH) *λ*~max~ (Δ*ε*) 207 (+8.3), 232 (−2.1), 252 (−0.7), 286 (−0.7) nm; IR (KBr) *ν*~max~ 3405, 2943, 1740, 1413, 1255, 1061, 820 cm^-1^; ^1^H and ^13^C NMR see [Table 1](#marinedrugs-17-00649-t001){ref-type="table"} and [Table 2](#marinedrugs-17-00649-t002){ref-type="table"}; HRESIMS *m/z* 343.1537 \[M + H\]^+^ (calcd. for C~20~H~23~O~5~, 343.1540).

*Penicixanthene* D (**4**)*:* white amorphous powder. \[*α*\]${}_{D}^{24}$ + 30.7 (*c* = 0.10, CHCl~3~). CD (*c* 2 × 10^-4^ mol/L, MeOH) *λ*~max~ (Δ*ε*) 196 (+25.1), 215 (−5.2), 231 (+1.9), 276 (+0.5) nm; IR (KBr) *ν*~max~ 3265, 1631, 1237 cm^-1^; ^1^H and ^13^C NMR see [Table 1](#marinedrugs-17-00649-t001){ref-type="table"} and [Table 2](#marinedrugs-17-00649-t002){ref-type="table"}; HRESIMS *m/z* 357.1700 \[M + H\]^+^ (calcd. for C~21~H~25~O~5~ 357.1697)

3.4. Preparation of (S)- and (R)-MTPA Ester Derivatives of Compounds **2** and **3** {#sec3dot4-marinedrugs-17-00649}
------------------------------------------------------------------------------------

Preparations of (*S*)- and (*R*)-MTPA ester derivatives of **2** and **3** were performed as described previously \[[@B6-marinedrugs-17-00649]\].

S-MTPA ester of **2** (**2a**): ^1^H NMR (CDCl~3~, 400 MHz) *δ*~H~: 7.23 (1H, d, *J* = 8.4 Hz, H-8), 7.15 (1H, t, *J* = 6.8 Hz, H-3), 6.96 (1H, dd, *J* = 8.8, 0.8 Hz, H-2), 6.81 (1H, d, *J* = 8.4 Hz, H-7), 6.46 (1H, dd, *J* = 8.8, 0.8 Hz, H-4), 5.34 (1H, m, H-11), 4.12 (1H, m, H-9), 3.59 (2H, m, H-14), 2.53 (1H, m, H-10b), 2.01 (2H, m, H-15), 1.74 (1H, m, H-10a), 1.17 (3H, d, *J* = 6.0 Hz, H-12), 0.77 (3H, t, *J* = 7.2 Hz, H-16). ESI-MS *m/z* 773.1 \[M − H\]^−^.

R-MTPA ester of **2** (**2b**): ^1^H NMR (CDCl~3~, 400 MHz) *δ*~H~: 7.29 (1H, m, H-8), 7.10 (1H, m, H-3), 6.99 (1H, m, H-2), 6.46 (1H, m, H-7), 6.23 (1H, m, H-4), 5.32 (1H, m, H-11), 4.08 (1H, m, H-9), 3.58 (2H, m, H-14), 2.33 (1H, m, H-10b), 1.99 (2H, m, H-15), 1.69 (1H, m, H-10a), 1.20 (3H, m, H-12), 0.72 (3H, m, H-16). ESI-MS *m/z* 773.1 \[M − H\]^−^.

S-MTPA ester of **3** (**3a**): ^1^H NMR (CDCl~3~, 400 MHz) *δ*~H~: 7.35 (1H, m, H-8), 7.30 (1H, m, H-3), 6.81 (1H, m, H-2), 6.69 (1H, m, H-7), 6.49 (1H, m, H-4), 5.34 (1H, m, H-11), 4.52 (1H, m, H-9), 3.58 (2H, m, H-14), 2.61 (1H, m, H-10b), 2.11 (2H, m, H-15), 2.01 (1H, m, H-10a), 1.30 (3H, d, *J* = 4.8 Hz, H-12), 0.74 (3H, t, *J* = 7.2 Hz, H-16). ESI-MS *m/z* 773.1 \[M − H\]^−^.

R-MTPA ester of **3** (**3b**): ^1^H NMR (CDCl~3~, 400 MHz) *δ*~H~: 7.30 (1H, m, H-8), 7.07 (1H, m, H-3), 6.96 (1H, m, H-2), 6.56 (1H, m, H-7), 6.36 (1H, m, H-4), 5.35 (1H, m, H-11), 4.59 (1H, m, H-9), 3.55 (2H, m, H-14), 2.56 (1H, m, H-10b), 2.10 (2H, m, H-15), 1.89 (1H, m, H-10a), 1.31 (3H, d, *J* = 6.0 Hz, H-12), 0.74 (3H, t, *J* = 6.4 Hz, H-16). ESI-MS *m/z* 773.1 \[M − H\]^−^.

3.5. Computational Section {#sec3dot5-marinedrugs-17-00649}
--------------------------

As previously reported \[[@B6-marinedrugs-17-00649],[@B15-marinedrugs-17-00649],[@B16-marinedrugs-17-00649]\].

3.6. Insecticidal Activities against Newly Hatched Larvae of Helicoverpa armigera Hubner {#sec3dot6-marinedrugs-17-00649}
----------------------------------------------------------------------------------------

Insecticidal activity against newly hatched larvae of *H. armigera* Hubner was evaluated according to the previously reported methods \[[@B6-marinedrugs-17-00649]\]. Newly hatched larvae were raised under 25 ± 1 °C and a relative humidity of 80%. DMSO was used as the negative control, azadirachtin was used as the positive control, and artificial diet was used as the blank control. The number of dead larvae was recorded on the 2nd, 4th, 6th, and 8th day after treatment, respectively \[[@B17-marinedrugs-17-00649]\].

3.7. Insecticidal Activities against Newly Hatched Larvae of Culex quinquefasciatus {#sec3dot7-marinedrugs-17-00649}
-----------------------------------------------------------------------------------

Insecticidal activity against newly hatched larvae of *C. quinquefasciatus* was evaluated according to the previously reported methods \[[@B17-marinedrugs-17-00649],[@B18-marinedrugs-17-00649]\]. DMSO was used as the negative control, azadirachtin was used as the positive control, and 10 mL dechlorinated water was used as the blank control. The number of dead larvae was recorded on the 1st, 2nd, 3rd, and 4th day after treatment, respectively.

4. Conclusions {#sec4-marinedrugs-17-00649}
==============

In summary, four new xanthene derivatives, penicixanthenes A--D (**1**--**4**), along with one known compound **5**, were obtained from the mangrove-derived fungus *Penicillium* sp. JY246. Furthermore, the absolute configurations of **2** and **3** were determined by modified Mosher's method and calculated electronic circular dichroism data. Compounds **2** and **3** showed growth inhibition activity against newly hatched larvae of *H. armigera* Hubner with the IC~50~ values 100 and 200 μg/mL, respectively. Compounds **1**, **3**, and **4** showed insecticidal activity against newly hatched larvae of *C. quinquefasciatus* with LC~50~ values of 38.5 (±1.16), 11.6 (±0.58), and 20.5 (±1) μg/mL, respectively.
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###### 

^1^H NMR data (400 MHz, *δ* in ppm, *J* in Hz) for **1**--**4**.

  Position   1 *^a^*                      2 *^b^*                      3 *^b^*                      4 *^b^*
  ---------- ---------------------------- ---------------------------- ---------------------------- ---------------------
  2          6.55, dd (8.0, 0.8)          6.35, dd (8.0, 0.8)          6.35, dd (8.0, 0.8)          6.81, d (8.0)
  3          7.04, dd (8.0, 8.0)          6.90, dd (8.0, 8.0)          6.94, dd (8.0, 8.0)          7.24, dd (8.0, 8.0)
  4          6.58, dd (8.0, 0.8)          6.26, dd (8.0, 0.8)          6.29, dd (8.0, 0.8)          7.06, d (8.0)
  5          6.52, dd (8.4, 1.2)                                                                    
  6          7.05, dd (8.4, 8.4)                                                                    
  7          6.50, dd (8.4, 1.2)          6.18, d (8.4)                6.16, d (8.4)                6.05, d (8.4)
  8                                       6.69, d (8.4)                6.57, d (8.4)                6.22, d (8.4)
  9          3.99, dd (12.4, 4.0)         4.52, dd (10.4, 8.0)         4.50, dd (7.6, 1.2)          4.63, m
  10a        1.79, td (12.4, 6.4)         1.49, td (13.6, 10.4)        1.76, ddd (13.6, 7.6, 4.4)   1.81, m
  10b        3.17, ddd (13.2, 4.0, 1.6)   2.44, ddd (13.6, 8.0, 1.6)   2.06, td (13.6, 1.2)         2.22, m
  11         4.64, m                      4.04, m                      3.82, m                      1.74, m
  12         1.39, d (6.4)                1.28, d (6.4)                1.25, d (6.4)                4.72, m
  14                                      3.11, t (7.2)                3.13, t (7.2)                3.12, t (7.2)
  15                                      1.71, m                      1.73, m                      1.72, m
  16                                      0.98, t (7.2)                0.99, t (7.2)                0.99, t (7.2)
  17                                                                                                3.57, s

*^a^* DMSO-*d*~6~ *^b^* CD~3~OD.
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###### 

^13^C NMR data (100 MHz, *δ* in ppm) for **1**--**4**.

  Position   1 *^a^*       2 *^b^*       3 *^b^*       4 *^b^*
  ---------- ------------- ------------- ------------- --------------
  1          156.9, C      159.7, C      159.9, C      141.6, C
  2          107.0, CH     109.3, CH     108.7, CH     110.8, CH
  3          127.8, CH     128.2, CH     128.6, CH     128.3, CH
  4          110.4, CH     108.7, CH     107.4, CH     123.3, CH
  4a         152.3, C      157.3, C      158.3, C      158.3, C
  4b         150.1, C      161,9, C      161,9, C      162.1, C
  5          110.2, CH     110.7, C      110.9, C      110.9, C
  6          127.9, CH     157.3, C      159.9, C      159.7, C
  7          106.5, CH     107.0, CH     106.0, CH     105.8, CH
  8          154.3, C      134.4, CH     136.6, CH     135.6, CH
  8a         109.3, C      126.2, C      125.3, C      125.4, C
  8b         109.1, C      114.3, C      111.9, C      128.9, C
  9          22.3, CH      31.8, CH      30.5, CH      32.3, CH
  10         33.0, CH~2~   40.4, CH~2~   36.1, CH~2~   23.9, CH~2~
  11         71.7, CH      73.4, CH      68.7, CH      28.2, CH~2~
  12         20.7, CH~3~   21.6, CH~3~   21.7, CH~3~   67.9, CH
  13                       209.7, C      209.8, C      209.9, C
  14                       47.6, CH~2~   47.6, CH~2~   47.2, CH~2~
  15                       19.1, CH~2~   19.1, CH~2~   19.2, CH~2~
  16                       14.3, CH~3~   14.3, CH~3~   14.3, CH~3~
  17                                                   59.9, OCH~3~

*^a^* DMSO-*d*~6~ *^b^* CD~3~OD.
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###### 

Biological activities of **1**--**5**.

  Compounds            IC~50~ (µg/mL)   LC~50~ (µg/mL)
  -------------------- ---------------- ----------------
  **1**                \>200            38.5 (±1.16)
  **2**                100              \>80
  **3**                200              11.6 (±0.58)
  **4**                \>200            23.5 (±1)
  **5**                \>200            \>80
  Azadirachtin *^a^*   25               8.8 (±0.58)

*^a^* Azadirachtin was used as a positive control.

[^1]: These authors contributed equally to this work.
